Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.8333.

A number of research firms have commented on TBPH. TD Cowen lifted their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings downgraded Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th. Finally, B. Riley Financial lifted their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.65% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE grew its holdings in Theravance Biopharma by 78.2% during the 1st quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after acquiring an additional 82,978 shares in the last quarter. California State Teachers Retirement System grew its holdings in Theravance Biopharma by 1,649.4% during the 1st quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock worth $662,000 after acquiring an additional 38,431 shares in the last quarter. Empowered Funds LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $900,000. Quantinno Capital Management LP grew its holdings in Theravance Biopharma by 32.9% during the 1st quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 4,463 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $1,672,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $16.25 on Wednesday. Theravance Biopharma has a one year low of $9.10 and a one year high of $21.03. The company has a market cap of $837.69 million, a price-to-earnings ratio of 7.39 and a beta of 0.19. The business’s 50 day moving average price is $15.85 and its 200 day moving average price is $17.51.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million during the quarter. On average, analysts predict that Theravance Biopharma will post 0.95 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.